Abstract
Sclerosing mesenteritis (SM) is a rare idiopathic fibroinflammatory disorder of the bowel mesentery adipose tissue.While the use of rituximab has been documented in IgG4-related SM, its effectiveness in idiopathic, IgG4-unrelatedSM remains unknown. We present a case of idiopathic SM successfully managed with rituximab, suggesting thatthis treatment may be an option for patients who either have contraindications to or have not responded to current first-line therapies.
Recommended Citation
Acharya, Indira; Field, Carey; and Clark, Mary E.
(2025)
"First Report of Successful Rituximab Therapy in Idiopathic Sclerosing Mesenteritis,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 15:
Iss.
4, Article 23.
DOI: 10.55729/2000-9666.1504
Available at:
https://scholarlycommons.gbmc.org/jchimp/vol15/iss4/23
